within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD09_Cefodizime;

model Cefodizime
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.4444444444444447e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.011,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0072,
    k12 = 2.3055555555555556e-06,
    k21 = 2.3055555555555556e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefodizime</td></tr><tr><td>ATC code:</td><td>J01DD09</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>11.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefodizime is a third-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It was used for the treatment of respiratory tract, urinary tract, skin, and soft tissue infections. Although approved and marketed in some countries, it is not widely used today due to the availability of newer antibiotics.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Barradell, LB, &amp; Brogden, RN (1992). Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. <i>Drugs</i> 44(5) 800–834. DOI:<a href=\"https://doi.org/10.2165/00003495-199244050-00008\">10.2165/00003495-199244050-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1280568/\">https://pubmed.ncbi.nlm.nih.gov/1280568</a></p></li><li><p>Cui, C, et al., &amp; Liu, D (2021). Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients. <i>Biopharmaceutics &amp; drug disposition</i> 42(1) 24–34. DOI:<a href=\"https://doi.org/10.1002/bdd.2258\">10.1002/bdd.2258</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33340419/\">https://pubmed.ncbi.nlm.nih.gov/33340419</a></p></li><li><p>Iwata, S, et al., &amp; Sunakawa, K (1991). [Influence of cefodizime on intestinal bacterial flora]. <i>The Japanese journal of antibiotics</i> 44(4) 412–425. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1880920/\">https://pubmed.ncbi.nlm.nih.gov/1880920</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DD09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefodizime;
